SCHEMBL4322720

SCHEMBL4322720

O=C(O)c1ccccc1C(=O)Nc1ccc(CBr)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.69
KMT2A Q03164 5/20 0.56
CYP1A2 P05177 1/20 0.55
GFER P55789 2/20 0.55
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
ALOX12 P18054 1/20 0.54
APEX1 P27695 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
FFAR1 O14842 1/20 0.52
MEN1 O00255 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
STAT1 P42224 1/20 0.51
NR1H4 Q96RI1 1/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4322719 0.93 KMT2A (0.63) ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL13927135 0.86 ALDH1A1 (0.92) ALDH1A1KMT2ACYP1A2GFERCYP3A4
SCHEMBL16426269 0.85 ALDH1A1 (0.71) ALDH1A1KMT2ACYP1A2GFERCYP3A4
SCHEMBL12615048 0.85 ALDH1A1 (0.71) ALDH1A1KMT2ACYP1A2GFERCYP3A4
SCHEMBL4335299 0.84 ALDH1A1 (0.69) ALDH1A1KMT2ACYP1A2GFERCYP3A4
SCHEMBL7829395 0.84 ALDH1A1 (0.70) ALDH1A1KMT2ACYP1A2GFERNPC1
SCHEMBL12700210 0.84 ALDH1A1 (0.69) ALDH1A1KMT2ACYP1A2GFERCYP3A4
SCHEMBL18784888 0.84 ALDH1A1 (0.69) ALDH1A1KMT2ACYP1A2GFERCYP3A4
SCHEMBL18132588 0.84 FFAR1 (0.73) ALDH1A1KMT2ACYP1A2GFERCYP3A4
SCHEMBL12614698 0.83 ALDH1A1 (0.67) ALDH1A1KMT2ACYP1A2GFERCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585997-B2 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof CHESTERFORD ENTERPRISES LIMITED (KY) 2009-09-08 US disclosed
US-7585997-B2 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof CHESTERFORD ENTERPRISES LIMITED (KY) 2009-09-08 US disclosed
US-7585997-B2 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof CHESTERFORD ENTERPRISES LIMITED (KY) 2009-09-08 US disclosed
EP-1709155-A4 COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF KASHFI KHOSROW (US) 2007-10-31 EP disclosed
EP-1709155-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF Kashfi, Khosrow (US) 2006-10-11 EP disclosed
US-20050182134-A1 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC. (CA) 2005-08-18 US disclosed
WO-2005065361-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF KASHFI KHOSROW (US) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182134-A1 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof PYGL, TP53, MKI67 ALDH1A1 565/4885KMT2A 4350/4885CYP1A2 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.